<i>Ficus elastica</i> phytochemicals mitigate hyperlipidemia <i>via</i> potential HMG-CoA reductase inhibition, reduced oxidative stress, and tissue preservation.
Ficus elastica phytochemicals showed potential antihyperlipidemic effects in a rat model, but further research is needed to assess their relevance in humans.
Where it sits
this study against the rest of the hmg (human menopausal gonadotropin) corpusSummary and findings
This study investigated the antihyperlipidemic and antioxidant properties of Ficus elastica phytochemicals in rats fed a high-fat diet. Subfraction 4 demonstrated HMG-CoA reductase inhibitory activity and improved lipid parameters compared to simvastatin. The study also reported a reduction in serum malondialdehyde and histological preservation of aortic endothelial integrity.
Abstract
<h4>Background and purpose</h4>Hyperlipidemia remains a major cardiovascular risk factor requiring novel therapeutic strategies beyond conventional statin therapy. This study investigated the antihyperlipidemic and antioxidant properties of <i>Ficus elastica</i> Roxb. ex Hornem. (Moraceae) phytochemicals through integrated <i>in vitro, in vivo</i>, and <i>in silico</i> approaches.<h4>Experimental approach</h4>Eight chromatographic subfractions were screened for 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity. Lipid profile, lipid peroxidation, and histopathology were evaluated in rats fed a high-fat diet to induce hyperlipidemia. Chemical composition was characterized using liquid chromatography high-resolution mass spectrometry (LC-HRMS) and subsequently investigated through molecular docking simulations.<h4>Findings/results</h4>Subfraction 4 demonstrated the strongest HMG-CoA reductase inhibitory activity. <i>In vivo</i> evaluation in high-fat diet-induced hyperlipidemic rats revealed dose-dependent improvements in all lipid parameters, with effects statistically comparable to simvastatin. Subfraction 4 additionally reduced serum malondialdehyde to levels statistically indistinguishable from normal controls, indicating restoration of oxidative homeostasis. Histological preservation of aortic endothelial integrity and elastic fiber organization was associated with reduced intima-media thickness, suggesting attenuation of early atherosclerotic changes. LC-HRMS analysis tentatively identified four major constituents, including phlorin, clausarinol, ginsenoyne C, and piptolinic acid A. Molecular docking analysis suggested that clausarinol and ginsenoyne C exhibited comparatively higher predicted binding affinity than simvastatin toward PCSK9 and PPAR-α, respectively.<h4>Conclusion and implications</h4>These findings support the potential of <i>F. elastica</i> phytochemicals as candidates for hyperlipidemia management.
Background
Hyperlipidemia is a significant cardiovascular risk factor, necessitating new therapeutic strategies beyond conventional statin therapy. Previous studies have indicated that phytochemicals may possess antihyperlipidemic and antioxidant properties. This study aims to explore the effects of Ficus elastica phytochemicals on lipid profiles and oxidative stress in a high-fat diet-induced hyperlipidemia model in rats.
Methods
The study utilized both in vitro and in vivo approaches, screening eight chromatographic subfractions for HMG-CoA reductase inhibitory activity. Rats were fed a high-fat diet to induce hyperlipidemia, and lipid profiles, lipid peroxidation, and histopathology were evaluated. The chemical composition was characterized using liquid chromatography high-resolution mass spectrometry (LC-HRMS).
Results
Subfraction 4 exhibited the strongest HMG-CoA reductase inhibitory activity. In vivo results demonstrated dose-dependent improvements in lipid parameters, with effects statistically comparable to simvastatin. Additionally, subfraction 4 reduced serum malondialdehyde to levels statistically indistinguishable from normal controls, indicating a restoration of oxidative homeostasis.
Interpretation
The findings suggest that Ficus elastica phytochemicals may have potential as antihyperlipidemic agents, comparable to known treatments like simvastatin. However, the clinical significance of these results remains uncertain, particularly given the study's rodent model and the need for further research in human populations. The small sample size and potential confounding factors limit the conclusions that can be drawn.
Key findings
- Subfraction 4 demonstrated the strongest HMG-CoA reductase inhibitory activity.
- In vivo evaluation revealed dose-dependent improvements in all lipid parameters, with effects statistically comparable to simvastatin.
- Subfraction 4 reduced serum malondialdehyde to levels statistically indistinguishable from normal controls.
- Histological preservation of aortic endothelial integrity and elastic fiber organization was associated with reduced intima-media thickness.
Limitations
- Rodent model may not fully translate to human outcomes.
- Small sample size in the study.
- Short duration of the study may not capture long-term effects.
- Not all relevant clinical endpoints were evaluated.